Cervical Cancer Rapid Diagnostic Test

The Aptima Virology portfolio fulfills the Hologic commitment to innovation by providing life-changing viral testing for viruses that affect patients worldwide.input:
output:Produce Accurate Resultsinput:
output:The industry-leading accuracy of Aptima assays for HIV-1, HCV, and HBV provides you with the assurance to provide repeatable, dependable results that you and your patients can rely on.input:
output:Achieve Peak Performanceinput:
output:Aptima Virology assays are engineered to operate on the Panther® system, which provides ultra-fast, true sample-to-result automation—everything your laboratory requires to satisfy the current molecular testing requirements.

Innovative Approaches to Virology Testinginput:
output:Hologic and the Aptima Virology portfolio have a history of innovation and leadership, which has contributed to significant advancements in the diagnosis and monitoring of the Human Immunodeficiency Virus (HIV) and Hepatitis B and C viruses (HBV and HCV). The FDA’s approval of qualitative nucleic acid amplification tests (NAATs) for HIV-1 and HCV in the early 2000s marked the beginning of this legacy. It proceeds with viral load testing for HIV-1, HCV, and HBV.input:
output:In the present day, the Aptima Virology portfolio is a critical resource for the clinical management of HIV-1, HCV, and HBV. These assays utilize Hologic’s proprietary real-time transcription mediated amplification (TMA) technology and are conducted on the fully automated Panther system.